Incorporating bortezomib into upfront treatment for multiple myeloma: Early results of total therapy 3

British Journal of Haematology

Volumn 138, Issue 2, 2007, Pages 176-185

  Barlogie, Bart ^a   Anaissie, Elias ^a   Van Rhee, Frits ^a   Haessler, Jeffrey ^b   Hollmig, Klaus ^a   Pineda Roman, Mauricio ^a   Cottler Fox, Michele ^a   Mohiuddin, Abid ^a   Alsayed, Yazan ^a   Tricot, Guido ^a   Bolejack, Vanessa ^b   Zangari, Maurizio ^a   Epstein, Joshua ^a   Petty, Nathan ^a   Steward, Douglas ^a   Jenkins, Bonnie ^a   Gurley, Jennifer ^a   Sullivan, Ellen ^a   Crowley, John ^b   Shaughnessy Jr , John D ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b USA   (United States)

Author keywords

Autotransplant; Bortezomib; Myeloma

Indexed keywords

BETA 2 MICROGLOBULIN; BORTEZOMIB; CISPLATIN; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; LACTATE DEHYDROGENASE; THALIDOMIDE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CD34 SELECTION; CHROMOSOME ANALYSIS; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA MICROARRAY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; LABORATORY TEST; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REMISSION; STATISTICAL ANALYSIS; SURVIVAL RATE; THROMBOEMBOLISM; TREATMENT RESPONSE; UNIVARIATE ANALYSIS;

AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; COMBINED MODALITY THERAPY; DEXAMETHASONE; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; STEM CELL TRANSPLANTATION; THALIDOMIDE; TREATMENT OUTCOME;

EID: 34250878387     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2007.06639.x     Document Type: Article

References (34)

1. Attal, M., Harousseau, J-L., Stoppa, A-M., Sotto, J-J., Fuzibet, J-G., Rossi, J-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., Payen, C. Bataille, R. (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. New England Journal of Medicine, 335, 91 97.
2. Attal, M., Harousseau, J.-L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.-G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., Voillat, L., Sotto, J.-J., Grosbois, B. Bataille, R. (2003) Single versus double autologous stem-cell transplantation for multiple myeloma. InterGroupe Francophone du Myélome. New England Journal of Medicine, 349, 2495 2502.
3. Barlogie, B., Alexanian, R., Pershouse, M., Smallwood, L. Smith, L. (1985) Cytoplasmic immunoglobulin content in multiple myeloma. Journal of Clinical Investigation, 76, 765 769.
4. Barlogie, B., Desikan, R., Eddlemon, P., Spencer, T., Zeldis, J., Munshi, N., Badros, A., Zangari, M., Anaissie, E., Epstein, J., Shaughnessy, J., Ayers, D., Spoon, D. Tricot, G. (2001) Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients. Blood, 98, 492 494.
5. Barlogie, B., Shaughnessy, J., Tricot, G., Jacobson, J., Zangari, M., Anaissie, E., Walker, R. Crowley, J. (2004) Treatment of multiple myeloma. Blood, 103, 20 32.
6. Barlogie, B., Tricot, G., Anaissie, E., Shaughnessy, J., Rasmussen, E., van Rhee, F., Fassas, A., Zangari, M., Hollmig, K., Pineda-Roman, M., Lee, C., Talamo, G., Thertulien, R., Kiwan, E., Krishna, S., Fox, M. Crowley, J. (2006) Effect of adding thalidomide to the treatment of multiple myeloma with tandem autotransplants. New England Journal of Medicine, 354, 1021 1030.
7. Blade, J., Samson, D., Reece, D., Apperley, J., Bjorkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S. Vesole, D. (1998) Criteria for evaluating response in patients with multiple myeloma treated by high-dose therapy and hematopoietic stem cell transplantation. The Myeloma, Subcommittee of the EBMT, (European Group for Blood, and Marrow Transplant), Chronic Leukaemia Working Party and the Myeloma, Working Committee of the International Bone, Marrow Transplant Registry & Autologous Blood, and Marrow Transplant Registry. British Journal of Haematology, 102, 1115 1123.
8. Cavo, M., Zamagni, E., Tosi, P., Tacchetti, P., Cellini, C., Cangini, D., de Vivo, A., Testoni, N., Nicci, C., Terragna, C., Grafone, T., Perrone, G., Ceccolini, M., Tura, S. Baccarani, S. (2005) Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood, 106, 35 39.
9. Child, J., Morgan, G., Davies, F., Owen, R., Bell, S., Hawkins, K., Brown, J., Drayson, M. Selby, P. (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. Medical Research Council Adult Leukaemia Working Party. New England Journal of Medicine, 348, 1857 1883.
10. Cox, D.R. (1972) Regression tables and life tables. Journal of the Royal Statistical Society B, 34, 187 202.
11. Facon, T., Mary, J., Harousseau, J., Harousseau, F., Huguet, F., Berthou, C., Grosbois, B., Anglaret, B., Azzedine, A. Rodon, P., on behalf of the Peny Intergroupe Francophone du Myélome (2006) Superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma [abstract]. Journal of Clinical Oncology, 24, 18S. Abstract 1.
12. Gooley, T., Leisenring, W., Crowley, J. Storer, B. (1999) Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Statistics in Medicine, 18, 695 706.
13. Hideshima, T. Anderson, K. (2002) Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nature Reviews Cancer, 2, 927 937.
14. Jagannath, S., Durie, B., Wolf, J., Camacho, E., Irwin, D., Lutzky, J., McKinley, M., Gabayan, E., Mazumder, A., Schenkein, D. Crowley, J. (2005) Bortezomib therapy alone and in combination with dexamethasone for patients with previously untreated symptomatic multiple myeloma. British Journal of Haematology, 129, 776 783.
15. Kaplan, E. Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457 481.
16. Lee, C-K., Barlogie, B., Munshi, N., Zangari, M., Fassas, A., Jacobson, J., van Rhee, F., Cottler-Fox, M., Muwalla, F. Guido, T. (2003) DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. Journal of Clinical Oncology, 21, 2732 2739.
17. Mateos, M-V., Hernández, J-M., Hernández, M-T., Gutiérrez, N-C., Palomera, L., Fuertes, M., Díaz-Mediavilla, J., Lahuerta, J-J., de la Rubia, J., Terol, M-J., Sureda, A., Bargay, J., Ribas, P., de Arriba, F., Alegre, A., Oriol, A., Carrera, D., García-Laraña, J., García-Sanz, R., Bladé, J., Prósper, F., Mateo, G., Esseltine, D-L., van de Velde, H. San Miguel, J-F. (2006) Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase I/II study. Blood, 108, 2165 2172.
18. Orlowski, R., Voorhees, P., Garcia, R., Hall, M., Kudrik, F., Allred, T., Johri, A., Jones, P., Ivanova Hendrik, A., Van Deventer, W., Gabriel, D., Shea, T., Mitchell, B., Adams, J., Esseltine, D-L., Trehu, E., Green, M., Lehman, M., Natoli, S., Collins, J., Lindley, C. Dees, E. (2005) Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood, 105, 3058 3065.
19. Palumbo, A., Bringhen, S., Caravita, T., Merla, E., Capparella, V., Callea, V., Cangialosi, C., Grasso, M., Rossini, F., Galli, M., Catalano, L., Zamagni, E., Petrucci, M.T., De Stefano, V., Ceccarelli, M., Ambrosini, M.T., Avonto, I., Falco, P., Ciccone, G., Liberati, A.M., Musto, P. Boccadoro, M. (2006a) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Italian Multiple Myeloma Network, GIMEMA. Lancet, 367, 825 831.
20. Palumbo, A., Falco, P., Falcone, A., Corradini, P., Di Raimondo, F., Giuliani, N., Rossi, G., Morabito, F., Canepa, L., Gozzetti, A., Ambrosini, M.T., Zeldis, J., Knight, R., Foà, R., Boccadoro, M. Petrucci, M.T. (2006b) Oral revlimid plus melphalan and prednisone (R-MP) for newly diagnosed multiple myeloma: results of a multicenter phase I/II study. Blood, 108, 240a. Abstract 800.
21. Palumbo, A., Ambrosini, M., Benevolo, G., Pregno, P., Pescosta, N., Callea, V., Cangialosi, C., Caravita, T., Morabito, F., Musto, P., Bringhen, S., Falco, P., Avonto, I., Cavallo, F. Boccadoro, M. (2006c) Bortezomib, melphalan, prednisone and thalidomide for relapsed multiple myeloma. Blood, Prepublished online December 5, 2006. doi:10·1182/blood-2006-08-042275.
22. Pineda-Roman, M., Bolejack, V., Arzoumanian, V., Anaissie, E., van Rhee, F., Zangari, M., Walker, R., Hollmig, K., Shaughnessy, Jr., J.D. Epstein, J., Krishna, S., Crowley, J. Barlogie, B. (2007) Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease. British Journal of Haematology, 136, 393 399.
23. Rajkumar, S., Hayman, S., Gertz, M., Dispenzieri, A., Lacy, M., Greipp, P., Geyer, S., Iturria, N., Fonseca, R., Lust, J., Kyle, R. Witzig, T. (2002) Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. Journal of Clinical Oncology, 21, 4319 4323.
24. Rajkumar, S., Hayman, S., Lacy, M., Dispenzieri, A., Geyer, S., Kabat, B., Zeldenrust, S., Kumar, S., Greipp, P., Fonseca, R., Lust, J., Russell, S., Kyle, R., Witzig, T. Gertz, M. (2005) Combination therapy with lenalidomide plus dexamethasone (REV/DEX) for newly diagnosed myeloma. Blood, 106, 4050 4053.
25. Richardson, P., Schlossman, R., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L., Doss, D., Kelly, K., McKenney, M., Mechlowicz, J., Freeman, A., Deocampo, R., Rich, R., Ryoo, J., Chauhan, D., Balinski, K., Zeldis, J. Anderson, K.C. (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood, 100, 3063 3067.
26. Richardson, P., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S., Srkalovic, G., Alsina, M., Alexanian, R., Siegel, D., Orlowski, R.Z., Kuter, D., Limentani, S., Lee, S., Hideshima, T., Esseltine, D.-L., Kauffman, M., Adams, J., Schenkein, D. Anderson, K. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. New England Journal of Medicine, 348, 2609 2617.
27. Richardson, ???, Jagannath, S., Avigan, D., Alsina, M., Schlossman, R., Mazumder, A., Munshi, N., Ghobrial, I., Doss, S., McKenney, M., Farrell, M., Warren, D., Lunde, L., Gourley, B., Vaccaro, B., Delaney, C., Pountney, S., Mitsiades, C., Hideshima, T., Byrne, C., Knight, R., Birner, A., Myers, T., Weller, E. Anderson, K. (2006) Lenalidomide plus bortezomib (Rev-Vel) in relapsed and/or refractory multiple myeloma (MM): final results of a multicenter Phase 1 trial. [abstract]. Blood, 108, 124a. Abstract 404.
28. Sawyer, J., Waldron, J., Jagannath, S. Barlogie, B. (1995) Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genetics and Cytogenetics, 82, 41 49.
29. Shaughnessy, J., Zhan, F., Burington, B., Huang, Y., Colla, S., Hanamura, I., Stewart, J., Kordsmeier, B., Randolph, C., Williams, D.R., Ziao, Y., Xu, H., Epstein, J., Anaissie, E., Krishna, S., Cottler-Fox, M., Hollmig, K., Mohiuddin, A., Pineda-Roman, M., Tricot, G., van Rhee, F., Sawyer, J., Alsayed, Y., Walker, R., Zangari, M., Crowley, J. Barlogie, B. (2006) A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood First Edition Paper, prepublished online November 14, 2006; doi:10.1182/blood-2006-07-038430.
30. Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., Zeldis, J., Barlogie, B., Siegel, D. Crowley, J. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. New England Journal of Medicine, 341, 1565 1571.
31. Wang, M., Delasalle, K., Giralt, A. Alexanian, R. (2005) Rapid control of previously untreated multiple myeloma with bortezomib-thalidomide-dexamethasone followed by early intensive therapy. Blood, 106, 231a. Abstract 784.
32. Zhan, F., Hardin, J., Kordsmeier, B., Bumm, K., Zheng, M., Tian, E., Sanderson, R., Yang, Y., Wilson, C., Zangari, M., Anaissie, E., Morris, C., Muwalla, F., van Rhee, F., Fassas, A., Crowley, J., Tricot, G., Barlogie, B. Shaughnessy, J. (2002) Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance and normal bone marrow plasma cells. Blood, 99, 1745 1757.
33. Zhan, F., Huang, Y., Colla, S., Stewart, J.P., Hanamura, I., Gupta, S., Epstein, J., Yaccoby, S., Sawyer, J., Burington, B., Anaissie, E., Hollmig, K., Pineda-Roman, M., Tricot, G., van Rhee, F., Walker, R., Zangari, M., Crowley, J., Barlogie, B. Shaughnessy, Jr., J.D. (2006) The molecular classification of multiple myeloma. Blood, 108, 2020 2028.
34. Zhan, F., Barlogie, B., Arzoumanian, V., Huang, Y., Williams, D.R., Hollmig, H.M., Tricot, T., van Rhee, F., Zangari, Z., Dhodapkar, M., John, D. Shaughnessy, Jr., J.D. (2007) Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood, 109, 1692 1700.